vs
Amentum Holdings, Inc.（AMTM）与博士伦健康（BHC）财务数据对比。点击上方公司名可切换其他公司
Amentum Holdings, Inc.的季度营收约是博士伦健康的1.2倍（$3.2B vs $2.8B），Amentum Holdings, Inc.净利率更高（1.4% vs -3.7%，领先5.0%），博士伦健康同比增速更快（9.3% vs -5.2%），博士伦健康自由现金流更多（$403.0M vs $-142.0M），过去两年Amentum Holdings, Inc.的营收复合增速更高（25.6% vs 14.0%）
本公司是总部位于美国达拉斯的跨国技术专业服务企业，面向全球企业、机构及政府部门客户提供工程、技术、建设服务以及科学与专项咨询服务，连续6年蝉联《工程新闻纪录》（ENR）全球顶尖设计企业500强榜首。
博士伦健康公司（Bausch Health）是一家业务多元化的北美跨国制药企业，全球总部位于加拿大魁北克省拉瓦尔，美国总部设在新泽西州布里奇沃特。公司专注于胃肠病、肝病、神经科、皮肤科、牙科、医疗美容等领域的药物研发、生产及销售，同时提供品牌药和仿制药产品，业务覆盖全球市场。
AMTM vs BHC — 直观对比
营收规模更大
AMTM
是对方的1.2倍
$2.8B
营收增速更快
BHC
高出14.5%
-5.2%
净利率更高
AMTM
高出5.0%
-3.7%
自由现金流更多
BHC
多$545.0M
$-142.0M
两年增速更快
AMTM
近两年复合增速
14.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.2B | $2.8B |
| 净利润 | $44.0M | $-103.0M |
| 毛利率 | 10.1% | — |
| 营业利润率 | 4.3% | 17.0% |
| 净利率 | 1.4% | -3.7% |
| 营收同比 | -5.2% | 9.3% |
| 净利润同比 | 266.7% | -205.1% |
| 每股收益（稀释后） | $0.18 | $-0.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMTMBHC
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.9B | $2.8B | ||
| Q3 25 | — | $2.7B | ||
| Q2 25 | $3.6B | $2.5B | ||
| Q1 25 | $3.5B | $2.3B | ||
| Q4 24 | $3.4B | $2.6B | ||
| Q3 24 | $2.2B | $2.5B | ||
| Q2 24 | $2.1B | $2.4B |
净利润AMTMBHC
| Q1 26 | $44.0M | — | ||
| Q4 25 | $40.0M | $-103.0M | ||
| Q3 25 | — | $179.0M | ||
| Q2 25 | $10.0M | $148.0M | ||
| Q1 25 | $4.0M | $-58.0M | ||
| Q4 24 | $12.0M | $98.0M | ||
| Q3 24 | $26.0M | $-85.0M | ||
| Q2 24 | $-26.0M | $10.0M |
毛利率AMTMBHC
| Q1 26 | 10.1% | — | ||
| Q4 25 | 10.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 10.3% | — | ||
| Q1 25 | 10.5% | — | ||
| Q4 24 | 10.6% | — | ||
| Q3 24 | 9.0% | — | ||
| Q2 24 | 9.6% | — |
营业利润率AMTMBHC
| Q1 26 | 4.3% | — | ||
| Q4 25 | 3.4% | 17.0% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | 2.9% | 17.5% | ||
| Q1 25 | 3.2% | 12.2% | ||
| Q4 24 | 3.9% | 21.8% | ||
| Q3 24 | 1.2% | 12.7% | ||
| Q2 24 | 4.2% | 16.2% |
净利率AMTMBHC
| Q1 26 | 1.4% | — | ||
| Q4 25 | 1.0% | -3.7% | ||
| Q3 25 | — | 6.7% | ||
| Q2 25 | 0.3% | 5.8% | ||
| Q1 25 | 0.1% | -2.6% | ||
| Q4 24 | 0.4% | 3.8% | ||
| Q3 24 | 1.2% | -3.4% | ||
| Q2 24 | -1.2% | 0.4% |
每股收益（稀释后）AMTMBHC
| Q1 26 | $0.18 | — | ||
| Q4 25 | $0.16 | $-0.30 | ||
| Q3 25 | — | $0.48 | ||
| Q2 25 | $0.04 | $0.40 | ||
| Q1 25 | $0.02 | $-0.16 | ||
| Q4 24 | $0.05 | $0.24 | ||
| Q3 24 | $0.31 | $-0.23 | ||
| Q2 24 | $-0.29 | $0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $247.0M | $1.3B |
| 总债务越低越好 | $3.9B | $20.8B |
| 股东权益账面价值 | $4.6B | $-554.0M |
| 总资产 | $11.2B | $26.4B |
| 负债/权益比越低杠杆越低 | 0.86× | — |
8季度趋势，按日历期对齐
现金及短期投资AMTMBHC
| Q1 26 | $247.0M | — | ||
| Q4 25 | $437.0M | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $738.0M | $1.7B | ||
| Q1 25 | $546.0M | $1.1B | ||
| Q4 24 | $522.0M | $1.2B | ||
| Q3 24 | $452.0M | $719.0M | ||
| Q2 24 | — | $595.0M |
总债务AMTMBHC
| Q1 26 | $3.9B | — | ||
| Q4 25 | $3.9B | $20.8B | ||
| Q3 25 | — | $21.0B | ||
| Q2 25 | $4.5B | $21.7B | ||
| Q1 25 | $4.7B | $21.5B | ||
| Q4 24 | $4.7B | $21.6B | ||
| Q3 24 | $4.7B | $21.5B | ||
| Q2 24 | — | $21.7B |
股东权益AMTMBHC
| Q1 26 | $4.6B | — | ||
| Q4 25 | $4.5B | $-554.0M | ||
| Q3 25 | — | $-565.0M | ||
| Q2 25 | $4.5B | $-764.0M | ||
| Q1 25 | $4.4B | $-1.2B | ||
| Q4 24 | $4.5B | $-1.3B | ||
| Q3 24 | $4.5B | $-1.2B | ||
| Q2 24 | $303.0M | $-1.2B |
总资产AMTMBHC
| Q1 26 | $11.2B | — | ||
| Q4 25 | $11.5B | $26.4B | ||
| Q3 25 | — | $26.8B | ||
| Q2 25 | $11.8B | $27.3B | ||
| Q1 25 | $12.0B | $26.4B | ||
| Q4 24 | $11.9B | $26.5B | ||
| Q3 24 | $12.0B | $26.5B | ||
| Q2 24 | — | $26.5B |
负债/权益比AMTMBHC
| Q1 26 | 0.86× | — | ||
| Q4 25 | 0.88× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.01× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.05× | — | ||
| Q3 24 | 1.05× | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-136.0M | $495.0M |
| 自由现金流经营现金流 - 资本支出 | $-142.0M | $403.0M |
| 自由现金流率自由现金流/营收 | -4.4% | 14.4% |
| 资本支出强度资本支出/营收 | 0.2% | 3.3% |
| 现金转化率经营现金流/净利润 | -3.09× | — |
| 过去12个月自由现金流最近4个季度 | $272.0M | $1.0B |
8季度趋势，按日历期对齐
经营现金流AMTMBHC
| Q1 26 | $-136.0M | — | ||
| Q4 25 | $270.0M | $495.0M | ||
| Q3 25 | — | $405.0M | ||
| Q2 25 | $106.0M | $289.0M | ||
| Q1 25 | $57.0M | $211.0M | ||
| Q4 24 | $110.0M | $601.0M | ||
| Q3 24 | — | $405.0M | ||
| Q2 24 | — | $380.0M |
自由现金流AMTMBHC
| Q1 26 | $-142.0M | — | ||
| Q4 25 | $261.0M | $403.0M | ||
| Q3 25 | — | $314.0M | ||
| Q2 25 | $100.0M | $190.0M | ||
| Q1 25 | $53.0M | $96.0M | ||
| Q4 24 | $102.0M | $495.0M | ||
| Q3 24 | — | $334.0M | ||
| Q2 24 | — | $302.0M |
自由现金流率AMTMBHC
| Q1 26 | -4.4% | — | ||
| Q4 25 | 6.6% | 14.4% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | 2.8% | 7.5% | ||
| Q1 25 | 1.5% | 4.2% | ||
| Q4 24 | 3.0% | 19.3% | ||
| Q3 24 | — | 13.3% | ||
| Q2 24 | — | 12.6% |
资本支出强度AMTMBHC
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 3.3% | ||
| Q3 25 | — | 3.4% | ||
| Q2 25 | 0.2% | 3.9% | ||
| Q1 25 | 0.1% | 5.1% | ||
| Q4 24 | 0.2% | 4.1% | ||
| Q3 24 | — | 2.8% | ||
| Q2 24 | — | 3.2% |
现金转化率AMTMBHC
| Q1 26 | -3.09× | — | ||
| Q4 25 | 6.75× | — | ||
| Q3 25 | — | 2.26× | ||
| Q2 25 | 10.60× | 1.95× | ||
| Q1 25 | 14.25× | — | ||
| Q4 24 | 9.17× | 6.13× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 38.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMTM
| Global Engineering Solutions Segment | $1.9B | 59% |
| Other U.S.Government Agencies | $400.0M | 12% |
| Fixed Price Contract | $380.0M | 12% |
| Commercial And International | $226.0M | 7% |
| Time And Materials Contract | $171.0M | 5% |
| Sales Channel Through Intermediary | $78.0M | 2% |
| Equity Method Investee | $50.0M | 2% |
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
